Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT03424005 (Morpheus-panBC) for Metastatic Breast Cancer is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-panBC) Phase 1, Phase 2 792 Immunotherapy
Clinical Trial NCT03424005 (Morpheus-panBC) is designed to study Treatment for Metastatic Breast Cancer. It is a Phase 1 Phase 2 interventional study that is recruiting, having started on March 30, 2018, with plans to enroll 792 participants. Led by Hoffmann-La Roche, it is expected to complete by September 30, 2030. The latest data from ClinicalTrials.gov was last updated on March 16, 2026.
Brief Summary
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer.
The study will be performed in two stages. During Stage 1, six cohorts will be enrolled in parallel in this study:
Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for ...
Show MoreOfficial Title
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
Conditions
Metastatic Breast CancerOther Study IDs
- Morpheus-panBC
- CO40115
- 2017-002038-21 (EudraCT Number)
- 2023-503629-20-00 (EU Study (CTIS) Number)
NCT ID Number
Start Date (Actual)
2018-03-30
Last Update Posted
2026-03-16
Completion Date (Estimated)
2030-09-30
Enrollment (Estimated)
792
Study Type
Interventional
PHASE
Phase 1
Phase 2
Phase 2
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active ComparatorAtezolizumab + Nab-Paclitaxel 1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Enrollment is closed. | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More Nab-Paclitaxel Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle. |
ExperimentalAtezolizumab + Nab-Paclitaxel + Tocilizumab 1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Enrollment is closed. | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More Tocilizumab Tocilizumab will be administered IV, 8 mg/kg on Day 1 of each 28-day cycle. Nab-Paclitaxel Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle. |
ExperimentalAtezolizumab + Sacituzumab Govitecan 1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Enrollment is closed. | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More Sacituzumab Govitecan Sacituzumab govitecan will be administered by IV infusion, 10 mg/kg, on Days 1 and 8 of each 21-day cycle. |
Active ComparatorCapecitabine 2L CIT-naïve participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).
Participants who progressed on treatment may have the option of receiving atezolizumab along with chemotherapy (chemo) during stage 2, provided they meet the eligibility criteria.
Enrollment is closed. | Capecitabine Capecitabine will be administered 1250 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day cycle. |
ExperimentalAtezolizumab + Ipatasertib 2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.
Enrollment is closed and participant follow-up is complete. | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More Ipatasertib Ipatasertib will be administered by mouth 400 mg once a day, on Days 1-21 of each 28-day cycle. |
ExperimentalAtezolizumab + SGN-LIV1A 2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Patients who experience loss of clinical benefit as determined by the investigator or unacceptable toxicity related to SGN-LIV1A will be given the option of receiving Atezolizumab + chemo during Stage 2, provided they meet the ...Show More | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More SGN-LIV1A SGN-LIV1A will be administered IV, 2.5 milligrams per kilogram (mg/kg) (maximum calculated dose 250 mg), on Day 1 of each 21-day cycle. |
ExperimentalAtezolizumab + Selicrelumab + Bevacizumab 2L-CIT-naïve participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.
Enrollment is closed and participant follow-up is complete. | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More Bevacizumab Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28-day cycle. Selicrelumab Selicrelumab will be administered by subcutaneous (SC) injection, at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (Cycle = 28 days). |
ExperimentalAtezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin) 2L CIT-naïve participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naïve participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemo (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as...Show More | Atezolizumab For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.
For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of eac...Show More Chemotherapy (Gemcitabine + Carboplatin or Eribulin) Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, on Days 1 and 8 of each 21-day cycle.
Or
Eribulin will be administered IV, 1.4 mg/m\^2 on Days 1 and 8 of each 21-day cycle. |
ExperimentalInavolisib + Abemaciclib + Fulvestrant HR+ participants will receive treatment with inavolisib plus abemaciclib plus fulvestrant until unacceptable toxicity or disease progression determined by the investigator according to RECIST v1.1. | Abemaciclib Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle. Fulvestrant For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:
Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.
For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Pa...Show More Inavolisib Inavolisib tablets will be administered by mouth OD. |
ExperimentalInavolisib + Ribociclib (Dose #1) + Fulvestrant HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Fulvestrant For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:
Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.
For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Pa...Show More Ribociclib (Dose #1) Ribociclib tablets will be administered by mouth once daily. Inavolisib Inavolisib tablets will be administered by mouth OD. |
ExperimentalInavolisib + Ribociclib (Dose #1) + Letrozole HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Ribociclib (Dose #1) Ribociclib tablets will be administered by mouth once daily. Letrozole Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle. Inavolisib Inavolisib tablets will be administered by mouth OD. |
ExperimentalInavolisib + Ribociclib (Dose #2) + Fulvestrant HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Fulvestrant For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:
Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.
For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Pa...Show More Ribociclib (Dose #2) Ribociclib tablets will be administered by mouth once daily. Inavolisib Inavolisib tablets will be administered by mouth OD. |
ExperimentalInavolisib + Ribociclib (Dose #2) + Letrozole HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Ribociclib (Dose #2) Ribociclib tablets will be administered by mouth once daily. Letrozole Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle. Inavolisib Inavolisib tablets will be administered by mouth OD. |
ExperimentalInavolisib + Abemaciclib + Letrozole HR+ participants will receive treatment with inavolisib plus abemaciclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Abemaciclib Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle. Letrozole Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle. Inavolisib Inavolisib tablets will be administered by mouth OD. |
ExperimentalInavolisib (Dose #1) + Trastuzumab Deruxtecan HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Inavolisib (Dose #1) Inavolisib tablets will be administered by mouth once daily. Trastuzumab Deruxtecan Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle. |
ExperimentalInavolisib (Dose #2) + Trastuzumab Deruxtecan HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Trastuzumab Deruxtecan Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle. Inavolisib (Dose #2) Inavolisib tablets will be administered by mouth once daily. |
ExperimentalEmpagliflozin (Empa) + Inavolisib (Inavo) + Fulvestrant (Fulv) ± Palbociclib (Palbo) Participants with locally advanced or metastatic, HR+, HER2- participants will receive empagliflozin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Fulvestrant For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:
Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.
For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Pa...Show More Inavolisib Inavolisib tablets will be administered by mouth OD. Empagliflozin Empagliflozin, administered orally, once daily (QD) Palbociclib For Empagliflozin + Inavolisib + Fulvestrant ± Palbociclib arm:
Palbociclib 125 mg administered orally, QD in Cycle 1 followed by 125 mg on Days 1-21 of each cycle.
For Metformin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1, followed by 125 mg on Days 1-21 of each cycle (Cycle=28 days). |
ExperimentalMetformin (Metf) + Inavolisib + Fulvestrant ± Palbociclib Participants with locally advanced or metastatic, HR+, HER2- participants will receive metformin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Fulvestrant For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:
Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.
For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Pa...Show More Inavolisib Inavolisib tablets will be administered by mouth OD. Palbociclib For Empagliflozin + Inavolisib + Fulvestrant ± Palbociclib arm:
Palbociclib 125 mg administered orally, QD in Cycle 1 followed by 125 mg on Days 1-21 of each cycle.
For Metformin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1, followed by 125 mg on Days 1-21 of each cycle (Cycle=28 days). Metformin Metf 1000 mg administered orally QD. |
ExperimentalInavolisib + Atirmociclib (Atirmo) + Fulvestrant Participants will receive inavolisib plus atirmociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1. | Fulvestrant For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:
Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.
For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Pa...Show More Inavolisib Inavolisib tablets will be administered by mouth OD. Atirmociclib Atirmociclib administered orally, BID on Days 1-28 for each 28-day cycle. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Objective Response Rate (ORR) | Baseline until disease progression or loss of clinical benefit (up to approximately 10 years) |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Progression Free Survival (PFS) | Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (up to approximately 10 years) as determined by the investigator according to RECIST v1.1 | |
Disease Control Rate (DCR) | Baseline through end of study (up to approximately 10 years) | |
Overall Survival (OS) | Randomization to death from any cause, through the end of study (up to approximately 10 years) | |
Overall Survival (at specific time-points) | 12 and 18 months | |
Duration of Response (DOR) | Randomization until first occurrence of a documented objective response to the first recorded occurrence of disease progression or death from any cause (whichever occurs first), through end of study (up to approximately 10 years) | |
Percentage of Participants with Adverse Events | Baseline to end of study (up to approximately 10 years) |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Patients must meet all of the following criteria to qualify for Stage 1 (all cohorts) and to qualify for Stage 2 (2L CIT-naïve cohort):
- Age >/= 18 years at the time of signing Informed Consent Form
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Able to comply with the study protocol, in the investigator's judgment
- Metastatic or inoperable locally advanced breast cancer
- Measurable disease (at least one target lesion) according to RECIST v1.1
- Life expectancy >/= 3 months, as determined by the investigator
- Tumor accessible for biopsy, unless archival tissue is available
- Availability of a representative tumor specimen that is suitable for biomarker analysis via central testing
- Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from breastfeeding and donating eggs, as outlined for each specific treatment arm
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm
Exclusion Criteria for Stage 1
- Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, CD40 agonists or interleukin-2 (IL-2) or IL-2-like compounds
- Biologic treatment (e.g., bevacizumab) within 2 weeks prior to initiation of study treatment, or other systemic treatment for TNBC within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
- Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
- Eligibility only for the control arm
Exclusion Criteria for Stage 1 (both cohorts) and Stage 2 (2L CIT-naïve cohort)
- Adverse events from prior anti-cancer therapy that have not resolved to Grade </= 1 or better with the exception of alopecia of any grade and Grade </= 2 peripheral neuropathy
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- Uncontrolled tumor-related pain
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- History of leptomeningeal disease
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- Active tuberculosis
- Severe infection within 4 weeks prior to initiation of study treatment
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
- Significant cardiovascular disease
- Prior allogeneic stem cell or solid organ transplantation
- History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study
Hoffmann-La Roche289 active studies to explore- Gilead Sciences183 active studies to explore
Study Central Contact
Contact: Reference Study ID Number: CO40115 https://forpatients.roche.com/, 888-662-6728 (U.S. and Canada), [email protected]
45 Study Locations in 9 Countries
California
City of Hope, Duarte, California, 91010, United States
Completed
University of California San Diego Medical Center, La Jolla, California, 92093, United States
Completed
Stanford Cancer Institute, Stanford, California, 94305, United States
Withdrawn
Colorado
Rocky Mountain Cancer Center - Longmont, Longmont, Colorado, 80501, United States
Completed
Florida
H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, 33612, United States
Completed
New Jersey
Hackensack Univ Medical Center, Hackensack, New Jersey, 07601, United States
Withdrawn
Regional Cancer Care Associates, LLC, Howell Township, New Jersey, 07731, United States
Withdrawn
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States
Withdrawn
New York
NYU Langone Medical Center, New York, New York, 10016, United States
Withdrawn
Pennsylvania
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States
Withdrawn
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States
Withdrawn
Tennessee
Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga, Tennessee, 37404, United States
Recruiting
The West Clinic, Germantown, Tennessee, 38138, United States
Recruiting
Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States
Recruiting
Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States
Recruiting
Texas
Texas Oncology-Plano East, Plano, Texas, 75075-7787, United States
Withdrawn
Victoria
Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, 3000, Australia
Recruiting
Western Australia
Fiona Stanley Hospital - Medical Oncology, Murdoch, Western Australia, 6150, Australia
Recruiting
Centre Léon Bérard, Lyon, 69008, France
Active, not recruiting
Institut régional du Cancer Montpellier, Montpellier, 34298, France
Withdrawn
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, 31059, France
Recruiting
Gustave Roussy, Villejuif, 94805, France
Recruiting
Universitätsklinikum Erlangen, Erlangen, 91054, Germany
Recruiting
Universitätsklinikum Essen, Essen, 45147, Germany
Recruiting
Rambam Medical Center, Haifa, 3109601, Israel
Recruiting
Shaare Zedek Medical Center, Jerusalem, 9103102, Israel
Recruiting
Hadassah University Medical Center, Jerusalem, 91120, Israel
Recruiting
Rabin MC, Petah Tikva, 55900, Israel
Recruiting
Sheba Medical Center, Ramat Gan, 5262100, Israel
Recruiting
Tel-Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel
Recruiting
Assuta Medical Centers, Tel Aviv, 69710, Israel
Recruiting
National Cancer Center Clinical Trials Center / Center for Breast Cancer, Goyang-si, 410-769, South Korea
Recruiting
Seoul National University Hospital, Seoul, 03080, South Korea
Recruiting
Severance Hospital, Seoul, 03722, South Korea
Recruiting
University of Ulsan College of Medicine - Asan Medical Center, Seoul, 05505, South Korea
Recruiting
Samsung Medical Center, Seoul, 06351, South Korea
Recruiting
Sevilla
Hospital Universitario Virgen Macarena, Seville, Sevilla, 41009, Spain
Recruiting
Hospital del Mar, Barcelona, 08003, Spain
Recruiting
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain
Recruiting
Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain
Recruiting
Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid, 28050, Spain
Recruiting
National Cheng Kung University Hospital, Tainan, 704302, Taiwan
Recruiting
National Taiwan University Hospital, Taipei, 100, Taiwan
Recruiting
Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom
Completed
Barts Health NHS Trust - St Bartholomew's Hospital, London, EC1A 7BE, United Kingdom
Completed